Connect
MJA
MJA

Liver failure associated with the use of black cohosh for menopausal symptoms

Belal Naser and Eckehard Liske
Med J Aust 2009; 190 (2): . || doi: 10.5694/j.1326-5377.2009.tb02292.x
Published online: 19 January 2009

To the Editor: The recent case report by Chow and colleagues raises questions about the causal link between black cohosh use and hepatotoxicity.1 The authors state that the patient had no history of “significant alcohol consumption”, but a presumably related adverse drug reaction report available from the Therapeutic Goods Administration reveals her alcohol use was “3–4 units [of] alcohol per day, [with] 1–2 alcohol-free days per week”.2 Alcohol misuse is a known risk factor for severe liver disease, as is gastric bypass surgery for obesity,3 also in the patient’s history. Unfortunately, because histological examination of the liver 6 weeks after first presentation found no recognisable residual hepatocytes, the diagnoses of alcoholic steatohepatitis, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis cannot be excluded. Without this, the specific conclusion of the liver biopsy that the “Massive hepatocellular necrosis [was] associated with herbal medication”2 cannot be substantiated.


  • Schaper and Brümmer GmbH and Co KG, Salzgitter, Germany.



Competing interests:

We are both employed by Schaper and Brümmer, manufacturer of black cohosh preparations.

  • 1. Chow ECY, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008; 188: 420-422. <MJA full text>
  • 2. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Public case detail for case number 220336, recorded as reported to the Adverse Drug Reactions Unit, 25 July 2006.
  • 3. Ong JP, Elariny H, Collantes R, et al. Predictors of non-alcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-315.
  • 4. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). London: EMEA, 2007. http://www.emea.europa. eu/pdfs/human/hmpc/26925806en.pdf (accessed Oct 2008).
  • 5. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Erratum: Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2008; 53: 869.
  • 6. Grant SM, Beck R v Pharmavite, Neutraceutical (2006). Case: 8:05-cv-00066-LES-TDT. United States District Court for the District of Nebraska. http://www.ahpa.org/Portals/0/pdfs/06_0908_BlackCohosh_NebraskaDistrictCt.pdf (accessed Oct 2008).
  • 7. Naser B, Liske E. Adverse liver reactions to black cohosh: are they accurately reported? Climacteric 2008; 11 Suppl 2: 114.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.